These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1551 related items for PubMed ID: 29604056

  • 1. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S, van der Helm D, Gray PC, Chen L, Klima I, Grosjean J, Burgmans MC, Farina-Sarasqueta A, Snaar-Jagalska EB, Stroka DM, Terracciano L, van Hoek B, Schaapherder AF, Osanto S, Thalmann GN, Verspaget HW, Coenraad MJ, Kruithof-de Julio M.
    J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
    [Abstract] [Full Text] [Related]

  • 2. Cripto-1 contributes to stemness in hepatocellular carcinoma by stabilizing Dishevelled-3 and activating Wnt/β-catenin pathway.
    Lo RC, Leung CO, Chan KK, Ho DW, Wong CM, Lee TK, Ng IO.
    Cell Death Differ; 2018 Aug; 25(8):1426-1441. PubMed ID: 29445127
    [Abstract] [Full Text] [Related]

  • 3. SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma.
    Wang M, Wang Z, Zhi X, Ding W, Xiong J, Tao T, Yang Y, Zhang H, Zi X, Zhou W, Huang G.
    Biomed Pharmacother; 2020 Sep; 129():110315. PubMed ID: 32554246
    [Abstract] [Full Text] [Related]

  • 4. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q, Zheng B, Meng S, Xu Y, Guo J, Chen LJ, Xiao J, Zhang W, Tan ZR, Tang J, Chen L, Chen Y.
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [Abstract] [Full Text] [Related]

  • 5. MYC-targeted WDR4 promotes proliferation, metastasis, and sorafenib resistance by inducing CCNB1 translation in hepatocellular carcinoma.
    Xia P, Zhang H, Xu K, Jiang X, Gao M, Wang G, Liu Y, Yao Y, Chen X, Ma W, Zhang Z, Yuan Y.
    Cell Death Dis; 2021 Jul 09; 12(7):691. PubMed ID: 34244479
    [Abstract] [Full Text] [Related]

  • 6. An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma.
    Li M, Zhang L, Ge C, Chen L, Fang T, Li H, Tian H, Liu J, Chen T, Jiang G, Xie H, Cui Y, Yao M, Li J.
    Oncotarget; 2015 Sep 22; 6(28):25149-60. PubMed ID: 26327240
    [Abstract] [Full Text] [Related]

  • 7. Cripto-1 promotes tumor invasion and predicts poor outcomes in hepatocellular carcinoma.
    Huang T, Guo YZ, Yue X, Zhang GP, Zhang Y, Kuang M, Peng BG, Li SQ.
    Carcinogenesis; 2020 Jul 10; 41(5):571-581. PubMed ID: 32649753
    [Abstract] [Full Text] [Related]

  • 8. Cripto-1 promotes tumor invasion and predicts poor outcomes in hepatocellular carcinoma.
    Huang T, Guo YZ, Yue X, Zhang GP, Zhang Y, Kuang M, Peng BG, Li SQ.
    Carcinogenesis; 2020 Jul 10; 41(5):571-581. PubMed ID: 32648918
    [Abstract] [Full Text] [Related]

  • 9. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
    Chen B, Wei W, Ma L, Yang B, Gill RM, Chua MS, Butte AJ, So S.
    Gastroenterology; 2017 Jun 10; 152(8):2022-2036. PubMed ID: 28284560
    [Abstract] [Full Text] [Related]

  • 10. PI16 attenuates response to sorafenib and represents a predictive biomarker in hepatocellular carcinoma.
    Wang P, Jiang Z, Liu X, Yu K, Wang C, Li H, Zhong L.
    Cancer Med; 2020 Oct 10; 9(19):6972-6983. PubMed ID: 32779397
    [Abstract] [Full Text] [Related]

  • 11. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells.
    Song Y, Pan G, Chen L, Ma S, Zeng T, Man Chan TH, Li L, Lian Q, Chow R, Cai X, Li Y, Li Y, Liu M, Li Y, Zhu Y, Wong N, Yuan YF, Pei D, Guan XY.
    Gastroenterology; 2015 Oct 10; 149(4):1068-81.e5. PubMed ID: 26099525
    [Abstract] [Full Text] [Related]

  • 12. HIF-1α-induced RIT1 promotes liver cancer growth and metastasis and its deficiency increases sensitivity to sorafenib.
    Song Z, Liu T, Chen J, Ge C, Zhao F, Zhu M, Chen T, Cui Y, Tian H, Yao M, Li J, Li H.
    Cancer Lett; 2019 Sep 28; 460():96-107. PubMed ID: 31247273
    [Abstract] [Full Text] [Related]

  • 13. LncRNA TTN-AS1 intensifies sorafenib resistance in hepatocellular carcinoma by sponging miR-16-5p and upregulation of cyclin E1.
    Zhou Y, Huang Y, Dai T, Hua Z, Xu J, Lin Y, Han L, Yue X, Ho L, Lu J, Ai X.
    Biomed Pharmacother; 2021 Jan 28; 133():111030. PubMed ID: 33378944
    [Abstract] [Full Text] [Related]

  • 14. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C, Dong X, Zhai B, Jiang X, Dong D, Li B, Jiang H, Xu S, Sun X.
    Oncotarget; 2015 Oct 06; 6(30):28867-81. PubMed ID: 26311740
    [Abstract] [Full Text] [Related]

  • 15. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
    Xu Y, Huang J, Ma L, Shan J, Shen J, Yang Z, Liu L, Luo Y, Yao C, Qian C.
    Cancer Lett; 2016 Feb 28; 371(2):171-81. PubMed ID: 26655273
    [Abstract] [Full Text] [Related]

  • 16. Silencing KIF14 reverses acquired resistance to sorafenib in hepatocellular carcinoma.
    Zhu Q, Ren H, Li X, Qian B, Fan S, Hu F, Xu L, Zhai B.
    Aging (Albany NY); 2020 Nov 16; 12(22):22975-23003. PubMed ID: 33203790
    [Abstract] [Full Text] [Related]

  • 17. Zinc finger protein 703 induces EMT and sorafenib resistance in hepatocellular carcinoma by transactivating CLDN4 expression.
    Wang H, Xu H, Ma F, Zhan M, Yang X, Hua S, Li W, Li Y, Lu L.
    Cell Death Dis; 2020 Apr 08; 11(4):225. PubMed ID: 32269215
    [Abstract] [Full Text] [Related]

  • 18. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
    Lai SC, Su YT, Chi CC, Kuo YC, Lee KF, Wu YC, Lan PC, Yang MH, Chang TS, Huang YH.
    J Exp Clin Cancer Res; 2019 Nov 26; 38(1):474. PubMed ID: 31771617
    [Abstract] [Full Text] [Related]

  • 19. Targeting AMP-activated kinase impacts hepatocellular cancer stem cells induced by long-term treatment with sorafenib.
    Bort A, Sánchez BG, Mateos-Gómez PA, Vara-Ciruelos D, Rodríguez-Henche N, Díaz-Laviada I.
    Mol Oncol; 2019 May 26; 13(5):1311-1331. PubMed ID: 30959553
    [Abstract] [Full Text] [Related]

  • 20. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
    Huang M, Chen C, Geng J, Han D, Wang T, Xie T, Wang L, Wang Y, Wang C, Lei Z, Chu X.
    Cancer Lett; 2017 Jul 10; 398():12-21. PubMed ID: 28377178
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 78.